These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38619037)

  • 41. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.
    Sartori A; Carle D; Freedman MS
    Expert Opin Pharmacother; 2014 May; 15(7):1019-27. PubMed ID: 24742277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role.
    Tan H; Li X; Li Y; He F; ZhangBao J; Zhou L; Yang L; Zhao C; Lu C; Dong Q; Li H; Quan C
    Front Immunol; 2024; 15():1343531. PubMed ID: 38558796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
    Scott LJ
    Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
    Papadopoulou A; Kappos L; Sprenger T
    Expert Opin Drug Saf; 2015 May; 14(5):749-59. PubMed ID: 25687236
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Teriflunomide: a review of its use in relapsing multiple sclerosis.
    Garnock-Jones KP
    CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223
    [TBL] [Abstract][Full Text] [Related]  

  • 47. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
    Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial).
    Ghezzi A; Neuteboom RF
    Mult Scler; 2023 May; 29(6):668-670. PubMed ID: 36960483
    [No Abstract]   [Full Text] [Related]  

  • 49. Teriflunomide, a potential novel cause of chronic active colitis.
    Kővári B; Zachs J; Murchie B; Lauwers GY
    Histopathology; 2020 Dec; 77(6):1000-1001. PubMed ID: 32323888
    [No Abstract]   [Full Text] [Related]  

  • 50. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
    Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P;
    Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
    Wolinsky JS; Narayana PA; Nelson F; Datta S; O'Connor P; Confavreux C; Comi G; Kappos L; Olsson TP; Truffinet P; Wang L; Miller A; Freedman MS;
    Mult Scler; 2013 Sep; 19(10):1310-9. PubMed ID: 23447359
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Brette S; Robinson M; Gold R;
    Mult Scler Relat Disord; 2017 Oct; 17():107-115. PubMed ID: 29055438
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.
    Mukhtar H; Yasmeen U; Siddiqa S; Sarfraz Z; Sarfraz A
    Mult Scler Relat Disord; 2022 Sep; 65():104002. PubMed ID: 35779372
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
    O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS;
    N Engl J Med; 2011 Oct; 365(14):1293-303. PubMed ID: 21991951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
    PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis.
    Zhou R; Li H; Yang H; Jiang F; Cai H; Li J; Chen S; Fang L; Yin J; Zeng Q
    Mult Scler Relat Disord; 2022 Feb; 58():103446. PubMed ID: 34929454
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
    Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
    J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW; Li D; Freedman MS; Bar-Or A; Rice GP; Confavreux C; Paty DW; Stewart JA; Scheyer R; ;
    Neurology; 2006 Mar; 66(6):894-900. PubMed ID: 16567708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.